Methicillin-Resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Methicillin-Resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global MRSA market. The report identifies the key trends shaping and driving the global MRSA market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MRSA sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global MRSA market was valued at $900m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.8% for the next seven years to reach $1,249m by 2017. The growth will primarily be driven by an increase in the average number of days spent in the hospitals due to inappropriate initial and steady increase in elderly amd immuno-suppressed population. At present the market has six approved therapies, out of which Vancomycin and Synercid (Quinupristin+Dalfopristin) are generic and rest four are branded drugs. Currently, the market is dominated by drugs like Vancomycin, Zyvox (linezolid) and Cubicin (daptomycin). As the disease is curable when identified in time, the unmet need seems to be low. Although the existing drugs such as Vancomycin, Zyvox, Cubicin, Tygacil (tygecycline), Vibativ (televancin) and Synercid are capable of curing the disease, still there are unmet needs which can be tapped with the emerging agents which have better safety.

Scope

The report provides information on the key drivers and challenges of the MRSA market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MRSA market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Penicillin-binding proteins (PBPs) binders, Transglycosylation and Transpeptidation inhibitor, Pleuromutilin bacterial protein synthesis inhibitor, CYP3A4-specific inhibitors and Membrane lysing action.
• Analysis of the current and future competition in the seven key countries MRSA market. Key market players covered are Takeda Pharmaceutical Company Limited/ Forest Laboratories, Merck & Co., Inc., Astrazeneca PLC, Trius Therapeutics, e-Therapeutics, Nabriva Therapeutics, TrioBiotics Pharma and Basilea Pharma.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MRSA therapeutics market.
• Analysis of key recent licensing and partnership agreements in MRSA market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global MRSA market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MRSA market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global MRSA market landscape? – Identify, understand and capitalize.

Table of contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 MRSA Therapeutics - Introduction 7
2.1 Overview 7
2.2 Pathophysiology of MRSA 8
2.3 Epidemiology of MRSA 9
2.3.1 Incidence 9
2.3.2 Prevalence 9
2.3.3 Hospitalization 9
2.4 Etiology of MRSA 9
2.5 Symptoms of MRSA 9
2.6 Diagnosis of MRSA 10
2.7 Treatment and Management Pattern of MRSA 10
2.8 GlobalData Pipeline Report Guidance 11

3 MRSA Therapeutics - Market Characterization 12
3.1 MRSA Therapeutics Market Size (2005-2010) – Global 12
3.2 MRSA Therapeutics Market Forecast (2010-2017) – Global 13
3.3 MRSA Therapeutics Market Size (2005-2010) – The US 14
3.4 MRSA Therapeutics Market Forecast (2010-2017) – The US 15
3.5 MRSA Therapeutics Market Size (2005-2010) – France 16
3.6 MRSA Therapeutics Market Forecast (2010-2017) – France 17
3.7 MRSA Therapeutics Market Size (2005-2010) – Germany 18
3.8 MRSA Therapeutics Market Forecast (2010-2017) – Germany 19
3.9 MRSA Therapeutics Market Size (2005-2010) – Italy 20
3.10 MRSA Therapeutics Market Forecast (2010-2017) – Italy 21
3.11 MRSA Therapeutics Market Size (2005-2010) – Spain 22
3.12 MRSA Therapeutics Market Forecast (2010-2017) – Spain 23
3.13 MRSA Therapeutics Market Size (2005-2010) – The UK 24
3.14 MRSA Therapeutics Market Forecast (2010-2017) – The UK 25
3.15 MRSA Therapeutics Market Size (2005-2010) – Japan 26
3.16 MRSA Therapeutics Market Forecast (2010-2017) – Japan 27
3.17 Drivers and Barriers for the MRSA therapeutics market 28
3.17.1 MRSA Therapeutics Market Drivers 28
3.17.2 MRSA Therapeutics Market Restraints 28
3.18 Opportunity and Unmet Need 29
3.19 Key Takeaway 30

4 MRSA Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profile for the Major Market Products 32
4.3.1 Vancocin HCL Capsules (vancomycin) 32
4.3.2 Zyvox (linezolid) 33
4.3.3 Cubicin (daptomycin) 34
4.3.4 Vibativ (televancin) 35
4.3.5 Tygacil (tigecycline) 36
4.3.6 Synercid (qinupristin+dalfopristin) 37
4.3.7 Teflaro (ceftaroline) 38
4.4 MRSA Therapeutics – Major Marketed Products Comparison 39
4.5 Key Takeaway 39

5 MRSA Therapeutics - Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 MRSA Therapeutics – Pipeline Assessment by Phase of Development 41
5.3.1 MRSA Therapeutics – Phase III Pipeline 41
5.3.2 MRSA Therapeutics – Phase II Pipeline 41
5.3.3 MRSA Therapeutics – Phase I Clinical Pipeline 42
5.3.4 MRSA Therapeutics – Preclinical Pipeline 43
5.3.5 MRSA Therapeutics – Discovery Pipeline 43
5.4 MRSA Therapeutics – Pipeline by Mechanism of Action 44
5.5 Technology Trends Analytical Framework 46
5.6 Most Promising Drugs Under Clinical Development 47
5.7 Most Promising Drug Profiles 48
5.7.1 Torezolid phosphate (TR-701, DA-7218) 48
5.8 Monoclonal antibodies in the Late Stage of Development for MRSA 49
5.8.1 Pagibaximab (PMAB, BSYX-A110) 49
5.8.2 Aurexis (tefibazumab) 50
5.9 Late Stage Molecules Under FDA Review 52
5.10 Key Takeaway 54

6 MRSA Therapeutics – Clinical Trials Mapping 55
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 55
6.2 Clinical Trials by Phase of Clinical Development 56
6.3 Clinical Trials by Trial Status 57
6.4 Prominent Sponsors 58
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 60

7 MRSA Therapeutics – Strategic Assessment 61
7.1 Key Events Impacting the Future Market 61
7.2 Future Market Competition Scenario 61

8 MRSA Therapeutics - Future Players 63
8.1 Introduction 63
8.2 Company Profiles 63
8.2.1 Takeda Pharmaceutical Company Limited 63
8.2.2 Merck & Co., Inc. 65
8.2.3 Basilea Pharmaceuticals 67
8.2.4 Inhibitex, Inc. 67
8.2.5 Biosynexus Incorporated 68
8.2.6 Forest Laboratories 68
8.2.7 The Medicines Company 70
8.2.8 Nabriva Therapeutics AG 71
8.2.9 AstraZeneca PLC 72
8.2.10 GlaxoSmithKline plc 73
8.2.11 e-Therapeutics plc 75
8.2.12 Tabular Presentation Details of Other Companies in the Pipeline 76
8.3 Key Takeaway 79

9 MRSA Therapeutics – Licensing & Partnership Deals 80

10 MRSA Therapeutics - Appendix 83
10.1 Market Definitions 83
10.2 Acronyms 83
10.3 Research Methodology 84
10.3.1 Coverage 84
10.3.2 Secondary Research 85
10.3.3 Forecasting 85
10.3.4 Primary Research 88
10.3.5 Expert Panel Validation 88
10.4 Contact Us 88
10.5 Disclaimer 88
10.6 Bibliography 89

List of Tables

Table 1: Epidemiologic Classification of Invasive MRSA 8
Table 2: Comparison of Risk Factors Associated with HA-MRSA and CA-MRSA Infection 8
Table 3: MRSA Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Table 4: MRSA Therapeutics, Major Market, Global, Forecast ($m), 2010–2017 13
Table 5: MRSA Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Table 6: MRSA Therapeutics Market, The US, Forecasts ($m), 2010–2017 15
Table 7: MRSA Therapeutics, France, Revenue ($m), 2005–2010 16
Table 8: MRSA Therapeutics Market, France, Forecasts ($m), 2010–2017 17
Table 9: MRSA Therapeutics, Germany, Revenue ($m), 2005–2010 18
Table 10: MRSA Therapeutics Market, Germany , Forecasts ($m), 2010–2017 19
Table 11: MRSA Therapeutics, Italy , Revenue ($m), 2005–2010 20
Table 12: MRSA Therapeutics Market, Italy, Forecasts ($m), 2010–2017 21
Table 13: MRSA Therapeutics, Spain, Revenue ($m), 2005–2010 22
Table 14: MRSA Therapeutics Market, Spain , Forecasts ($m), 2010–2017 23
Table 15: MRSA Therapeutics, The UK, Revenue ($m), 2005–2010 24
Table 16: MRSA Therapeutics Market, The UK, Forecasts ($m), 2010–2017 25
Table 17: MRSA Therapeutics, Japan, Revenue ($m), 2005–2010 26
Table 18: MRSA Therapeutics Market, Japan, Forecasts ($m), 2010–2017 27
Table 19: Major Marketed Products Comparison in MRSA Therapeutics Market, 2010 39
Table 20: MRSA Therapeutics – Phase III Pipeline, 2010 41
Table 21: MRSA Therapeutics – Phase II Pipeline, 2010 41
Table 22: MRSA Therapeutics – Phase I Pipeline, 2010 42
Table 23: MRSA Therapeutics – Preclinical Pipeline, 2010 43
Table 24: MRSA Therapeutics – Discovery Pipeline, 2010 43
Table 25: MRSA Therapeutics Market – Most Promising Drugs Under Clinical Development, 2010 47
Table 26: Comparison of linezolid and torezolid 49
Table 27: Development status of Ceftobiprole 52
Table 28: Development status of Dalbavancin 52
Table 29: Development status of Iclaprim 53
Table 30: MRSA Therapeutics – Clinical Trials by Country, 2011 55
Table 31: MRSA Therapeutics, Major Markets – Clinical Trials by Phase, 2011 56
Table 32: MRSA Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 57
Table 33: MRSA Therapeutics, Major Markets, Prominent Sponsors, 2011 59
Table 34: MRSA Therapeutics, Major Markets, Clinical Trials of Top Ten Companies by Phase, 2011 60
Table 35: Takeda Pipeline Products 65
Table 36: Merck Pipeline Products 67
Table 37: Basilea Pipeline Products 67
Table 38: Inhibitex, MRSA Therapeutic Pipeline 68
Table 39: Forest Pipeline Products 70
Table 40: The Medicine Company Pipeline Products 71
Table 41: Nabriva Pipeline Products 72
Table 42: Astrazeneca Pipeline Products 73
Table 43: GlaxoSmithKline Pipeline Products 75
Table 44: e-Therapeutics Pipeline Products 76
Table 45: MRSA Therapeutics – Other Companies in the Pipeline, 2011 76
Table 46: MRSA Therapeutics, Global, Deals, 2009-2011 80

List of Figures

Figure 1: Treatment and Management Pattern for MRSA Infected Outpatients 10
Figure 2: MRSA Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Figure 3: MRSA Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Figure 4: MRSA Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Figure 5: MRSA Therapeutics Market, The US, Forecast ($m), 2010–2017 15
Figure 6: MRSA Therapeutics Market, France, Revenue ($m), 2005–2010 16
Figure 7: MRSA Therapeutics Market, France, Forecast ($m), 2010–2017 17
Figure 8: MRSA Therapeutics Market, Germany, Revenue ($m), 2005–2010 18
Figure 9: MRSA Therapeutics Market, Germany, Forecast ($m), 2010–2017 19
Figure 10: MRSA Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Figure 11: MRSA Therapeutics Market, Italy, Forecast ($m), 2010–2017 21
Figure 12: MRSA Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Figure 13: MRSA Therapeutics Market, Spain, Forecast ($m), 2010–2017 23
Figure 14: MRSA Therapeutics Market, The UK, Revenue ($m), 2005–2010 24
Figure 15: MRSA Therapeutics Market, The UK, Forecast ($m), 2010–2017 25
Figure 16: MRSA Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Figure 17: MRSA Therapeutics Market, Japan, Forecast ($m), 2010–2017 27
Figure 18: Opportunity and Unmet Need in the MRSA Therapeutics Market 29
Figure 19: Strategic Competitor Assessment, 2010 31
Figure 20: MRSA Therapeutics – Clinical Pipeline by Mechanism of Action, 2010 44
Figure 21: MRSA Therapeutics Market – Pipeline by Phase of Development, 2010 45
Figure 22: Technology Trends Analytics Framework, 2010 46
Figure 23: Technology Trends Analytics Framework – Description, 2010 47
Figure 24: MRSA Therapeutics – Clinical Trials by Country, 2011 55
Figure 25: MRSA Therapeutics, Major Markets – Clinical Trials by Phase, 2011 56
Figure 26: MRSA Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 57
Figure 27: MRSA Therapeutics, Major Markets, Overall Sponsors, 2011 58
Figure 28: MRSA Therapeutics, Major Markets, Overall Sponsors, 2011 58
Figure 29: MRSA Therapeutics, Major Markets, Clinical Trials of Top Ten Companies by Phase, 2011 60
Figure 30: MRSA Therapeutics Market, Drivers and Restraints 2011 61
Figure 31: Implications for Future Market Competition in the MRSA Therapeutics Market, 2011 61
Figure 32: MRSA Therapeutics Market – Clinical Pipeline by Company, 2011 63
Figure 33: GlobalData Market Forecasting Model 87